Cooper Companies (NASDAQ:COO) Earns Market Perform Rating from William Blair

Cooper Companies (NASDAQ:COO)‘s stock had its “market perform” rating reissued by research analysts at William Blair in a research note issued on Thursday, MarketBeat.com reports.

A number of other brokerages also recently issued reports on COO. Needham & Company LLC cut their price target on shares of Cooper Companies from $86.00 to $73.00 and set a “buy” rating for the company in a report on Thursday. UBS Group decreased their price objective on Cooper Companies from $75.00 to $66.00 and set a “neutral” rating on the stock in a report on Thursday. Piper Sandler lowered Cooper Companies from an “overweight” rating to a “neutral” rating and set a $59.00 price objective for the company. in a research report on Thursday. JPMorgan Chase & Co. cut their target price on Cooper Companies from $80.00 to $71.00 and set a “neutral” rating for the company in a research note on Friday, June 5th. Finally, The Goldman Sachs Group set a $61.00 target price on Cooper Companies in a research report on Wednesday, May 27th. Five research analysts have rated the stock with a Buy rating, ten have issued a Hold rating and three have issued a Sell rating to the company. Based on data from MarketBeat, the stock has a consensus rating of “Hold” and a consensus price target of $74.33.

Cooper Companies Trading Down 15.2%

Shares of COO stock traded down $9.64 on Thursday, hitting $53.84. 2,969,847 shares of the stock traded hands, compared to its average volume of 2,346,635. The company has a debt-to-equity ratio of 0.23, a quick ratio of 0.78 and a current ratio of 1.27. Cooper Companies has a twelve month low of $51.01 and a twelve month high of $89.83. The firm’s 50-day moving average price is $72.42 and its two-hundred day moving average price is $70.02. The stock has a market capitalization of $10.50 billion, a PE ratio of 45.81, a PEG ratio of 1.77 and a beta of 0.82.

Cooper Companies (NASDAQ:COO) last released its quarterly earnings data on Wednesday, September 9th. The medical device company reported $1.15 earnings per share (EPS) for the quarter, topping the consensus estimate of $1.12 by $0.03. Cooper Companies had a net margin of 5.57% and a return on equity of 10.88%. The firm had revenue of $1.07 billion during the quarter, compared to analysts’ expectations of $1.10 billion. During the same period last year, the business earned $0.49 earnings per share. Cooper Companies’s revenue was up .5% compared to the same quarter last year. Cooper Companies has set its Q4 2026 guidance at 1.050-1.090 EPS and its FY 2026 guidance at 4.510-4.550 EPS. As a group, analysts anticipate that Cooper Companies will post 4.63 EPS for the current year.

Cooper Companies announced that its board has initiated a share repurchase plan on Wednesday, September 9th that authorizes the company to repurchase $3.00 billion in outstanding shares. This repurchase authorization authorizes the medical device company to repurchase up to 22.7% of its shares through open market purchases. Shares repurchase plans are generally a sign that the company’s board believes its shares are undervalued.

Hedge Funds Weigh In On Cooper Companies

A number of hedge funds have recently made changes to their positions in the stock. MIRAE ASSET GLOBAL ETFS HOLDINGS Ltd. increased its holdings in Cooper Companies by 48.9% in the 1st quarter. MIRAE ASSET GLOBAL ETFS HOLDINGS Ltd. now owns 22,407 shares of the medical device company’s stock valued at $1,890,000 after purchasing an additional 7,363 shares during the last quarter. First Trust Advisors LP lifted its stake in Cooper Companies by 115.8% during the second quarter. First Trust Advisors LP now owns 136,334 shares of the medical device company’s stock worth $9,702,000 after purchasing an additional 73,165 shares in the last quarter. Cresset Asset Management LLC acquired a new position in Cooper Companies during the second quarter worth $291,000. Cerity Partners LLC boosted its position in shares of Cooper Companies by 4.4% during the second quarter. Cerity Partners LLC now owns 17,870 shares of the medical device company’s stock worth $1,272,000 after buying an additional 757 shares during the period. Finally, Daiwa Securities Group Inc. boosted its position in shares of Cooper Companies by 2.8% during the second quarter. Daiwa Securities Group Inc. now owns 35,839 shares of the medical device company’s stock worth $2,551,000 after buying an additional 973 shares during the period. Hedge funds and other institutional investors own 24.39% of the company’s stock.

Key Cooper Companies News

Here are the key news stories impacting Cooper Companies this week:

• Positive Sentiment: COO reported fiscal Q3 adjusted EPS of $1.15, above the $1.11-$1.12 analyst consensus. GAAP EPS was $2.24, helped by a $307.2 million benefit from the favorable completion of a U.K. tax examination. Free cash flow increased 66% to $273 million. CooperCompanies Announces Third Quarter 2026 Results
• Positive Sentiment: The board expanded the share-repurchase authorization from $2 billion to $3 billion, potentially allowing repurchases of up to 22.7% of outstanding shares. Management also said it remains open to strategic alternatives that could create shareholder value. CooperCompanies Completes Strategic Review
• Neutral Sentiment: Third-quarter revenue rose roughly 1% year over year to $1.066 billion, with CooperVision revenue flat at $717 million and CooperSurgical revenue up 2% to $349.2 million. The results show continued profitability but limited underlying growth.
• Negative Sentiment: Revenue missed the approximately $1.10 billion consensus estimate, while fiscal 2026 adjusted EPS guidance was cut to $4.51-$4.55 from expectations near $4.63. Fourth-quarter EPS guidance of $1.05-$1.09 also trails the roughly $1.20 consensus. Analysts Lower Forecasts Following Q3 Results
• Negative Sentiment: CooperCompanies ended its strategic review by retaining CooperSurgical because potential offers were not attractive enough. Investors appear disappointed that the company will not receive sale proceeds, amid valuation pressure from a new non-hormonal IUD competitor and recent fertility-litigation costs.
• Negative Sentiment: Analysts responded by lowering price targets, including Needham to $73 from $86 and Bank of America to $65 from $80. Bank of America maintained a neutral rating, while the forecast reductions reinforced concerns about near-term growth.

Cooper Companies Company Profile

Cooper Companies, Inc is a global medical device company headquartered in San Ramon, California. Founded in 1958, the company develops, manufactures and markets products through two primary business segments: CooperVision and CooperSurgical.

CooperVision specializes in contact lenses, including daily disposable, toric, multifocal, multifocal toric, specialty and myopia-management lenses. Its products are designed to address a range of vision-correction needs, including astigmatism, presbyopia and irregular corneas.